Mesoblast Net Income vs. Shares Outstanding
| MESO Stock | USD 14.36 -0.42 -2.84% |
Net Loss | First Reported 2012-09-30 | Previous Quarter -27.1 M | Current Value -27.1 M | Quarterly Volatility 12.9 M |
Macro event markers
This module outlines profitability structure for Mesoblast using margin and return relationships. The information is based on reported accounting data. Figures reflect how income relates to operational and balance sheet components.
Mesoblast | Build portfolio with Mesoblast Stock |
Macro event markers
Earnings Share -0.85 | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than book value, which reflects Mesoblast accounting equity. Mesoblast's market capitalization is 1.94 B. At P/B 3.22, Mesoblast trades at a significant premium to book value. Enterprise value stands at 1.88 B. Intrinsic value for Mesoblast synthesizes operating data into a single estimate that complements price and book value. Reconciling these perspectives is central to structured valuation analysis.
For Mesoblast, intrinsic value is a model-driven estimate while price is a market-driven observation. For Mesoblast, key inputs include a P/B ratio of 3.22, ROE of -18.95%, and revenue of 17.2 M. Where Mesoblast trades at any moment depends on the balance of buying and selling pressure. This dataset reflects observed data and is not advisory in nature.
Mesoblast Shares Outstanding vs. Net Income Fundamental Analysis
Comparative pricing analysis measures Mesoblast's value against industry norms. Mesoblast lands at #3 in net income compared to key competitors. It lands at #5 in shares outstanding compared to key competitors . Mesoblast shows Net Loss compressing by approximately 5.26% year over year. A year ago, Mesoblast reported Net Loss at -91.93 Million. Valuation benchmarking positions Mesoblast within industry multiples.Mesoblast Shares Outstanding vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Mesoblast |
| = | -102.14 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertible bonds.
Mesoblast |
| = | 128.29 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Mesoblast Shares Outstanding Comparison
Mesoblast is currently under evaluation in shares outstanding compared to key competitors.
Mesoblast Profitability Projections
The most important aspect of a successful company is its ability to generate a profit, and for investors in Mesoblast profitability is a critical portfolio criterion. The direction and pace of Mesoblast's profitability changes provide forward-looking signals for investors. Profitability that depends heavily on non-operating items may not be sustainable in the long run. The operating margin stands at -3.0% while return on equity is -19.0%. These metrics serve as a key input for both valuation models and portfolio construction decisions. Recent net income of -102.1 M reflects the bottom-line result of these profitability dynamics.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | 114.4 M | 120.1 M | |
| Operating Income | -56.2 M | -59 M | |
| Income Before Tax | -91.6 M | -87 M | |
| Total Other Income Expense Net | -35.4 M | -33.7 M | |
| Net Loss | -91.9 M | -87.3 M | |
| Income Tax Expense | 297 K | 311.9 K | |
| Net Loss | -91.9 M | -96.5 M | |
| Net Loss | -73.7 M | -77.4 M | |
| Net Interest Income | -17.1 M | -18 M | |
| Interest Income | 4.1 M | 4.3 M | |
| Change To Netincome | 19.5 M | 20.5 M | |
| Net Loss | -0.10 | -0.11 | |
| Income Quality | 0.44 | 0.42 | |
| Net Income Per E B T | 0.90 | 0.73 |
Mesoblast Profitability Driver Comparison
The profitability drivers of Mesoblast most directly shape its earnings and investment appeal. Investors face a broad range of unforeseen events - from market shocks to policy shifts - that can disrupt Mesoblast's profitability and fundamentally alter the overall investment thesis.
Earnings per Share Projection vs Actual
Use Mesoblast in pair-trading
Pair trading with Mesoblast can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Mesoblast Pair Trading
Mesoblast Pair Trading Analysis
Pair-trading logic also applies to tax-loss harvesting: by identifying an asset with near-identical factor exposures to Mesoblast, investors can effectively maintain a synthetic Mesoblast position while the wash-sale clock resets.
The correlation structure around Mesoblast evolves as market regimes change. Assets that were once uncorrelated with Mesoblast may become correlated during crises, so investors should monitor rolling correlations alongside static long-run averages.
Hedging context for Mesoblast can be developed through Correlation analysis and pair trading analysis. Pair analysis can span stocks within the same sector or across different segments. Pair dynamics can shift during periods of market stress or structural change. All values are computed from publicly available trading activity and price records.Use Investing Themes to Complement your Mesoblast position
At 1.94 Billion in the Biotechnology space, Mesoblast smaller-cap profile gives investors a structured starting point for building sector-aligned themes. Anchoring a Biotechnology theme around Mesoblast at 1.94 Billion can be tuned for upside participation or tighter downside control depending on Healthcare outlook.
Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
Explore the Disruptive Technologies Theme as a thematic allocation that can be optimized for return targets or risk constraints.
| View All Next | Launch |